New ‘Cancer-Stopping Pill’ That Can ‘Annihilate’ Tumors

New ‘Cancer-Stopping Pill’ That Can ‘Annihilate’ Tumors

Developed by U.S. Scientists

By Mimi Nguyen Ly via The Epoch Times

A group of U.S. researchers has developed a new “cancer-killing pill” that could target and kill solid annihilate tumors while leaving healthy cells unharmed.

That’s according to their preclinical research findings, published Aug. 1 in the Cell Chemical Biology journal.

The City of Hope-developed small molecule AOH1996 targets a cancerous variant of the protein PCNA. In its mutated form, PCNA is critical in DNA replication and repair of all expanding tumors. Image shows untreated cancer cells (L) and cancer cells treated with AOH1996 (R) undergoing programmed cell death (violet). (Courtesy of City of Hope)

Titled “Small Molecule Targeting of Transcription-Replication Conflict for Selective Chemotherapy,” the study found that a drug the researchers developed was able to selectively disrupt DNA replication and repair in cancer cells.

The drug is called AOH1996. It was named after Anna Olivia Healey, who was born in 1996 and died of a rare form of cancer called neuroblastoma when she was 9 years old.

Linda Malkas, a senior author of the new study based at the City of Hope, has been developing the drug over the past two decades.

City of Hope is a private, non-profit clinical research center, hospital, and graduate school in Duarte, California. It’s one of the largest cancer research and treatment organizations in the United States.

According to a press release from City of Hope, the AOH1996 “appears to annihilate all solid tumors.”

Now that research has demonstrated promising results in cell and animal models, the new drug is being tested in humans in a Phase 1 clinical trial, Ms. Malkas said in a statement.

Unique Mechanism

The preclinical study explains how AOH1996 targets a cancerous version of the protein, called proliferating cell nuclear antigen (PCNA).

The cancerous variant of PCNA “is critical in DNA replication and repair” of all cancerous tumors, but the new drug AOH1996 inhibits PCNA, the City of Hope noted in its release.

Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells,” Ms. Malkas said.

“PCNA is like a major airline terminal hub containing multiple plane gates,” she explained. “Our cancer-killing pill [AOH1996] is like a snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells.”

Given orally at a certain dose, AOH1996 “suppresses tumor growth but causes no discernable side effect,” authors wrote in the study.

Most other targeted cancer therapies focus on a single pathway, which allows cancer cells to mutate and eventually become resistant to the therapy, Ms. Malkas noted. The unique mechanism of AOH1996 that enables it to target the mutated versions of PCNA sets it apart from other currently available therapies.

Ms. Malkas said results “have been promising” and they suggest that AOH1996 “can suppress tumor growth as a monotherapy or combination treatment in cell and animal models without resulting in toxicity.”

Further Studies Ahead

PCNA was once thought to be too challenging for targeted therapy.

“No one has ever targeted PCNA as a therapeutic because it was viewed as ‘undruggable,’ but clearly City of Hope was able to develop an investigational medicine for a challenging protein target,” lead author of the study, Long Gu, said in a statement.

Read more here…


(TLB) published this article By Mimi Nguyen Ly via The Epoch Times as posted at ZeroHedge

Header featured image (edited) credit:   Cancer treatment/pills/

Emphasis added by (TLB)



Stay tuned to …


The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)


Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.


Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.


Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.

2 Comments on New ‘Cancer-Stopping Pill’ That Can ‘Annihilate’ Tumors

  1. So… Is THIS also a form of gene-modifying (gene-altering) mRNA or DNA??? Is that how they “developed” this so quickly (2 years)???

  2. That sounds great, so who is going to buy the the patents just to bury this? Somebody will, they don’t want Cancer to end, ever. And ladies, keep wearing those bras.

Leave a Reply

Your email address will not be published.